Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
In the news...
* Bristol Myers Squibb closes immuno-oncology, cell therapy-focused Redwood City site
https://qtx.omeclk.com/portal/wts/ue%5EcmQ6fDTqbb7gFaA2Tw6mveE4b6dzMN9fA7fPsTa
https://www.fiercebiotech.com/biotech/bms-more-likely-bet-bolt-ons-after-recent-buying-spree
* Gilead gives up on $4.9B antibody as solid tumor plan unravels
https://qtx.omeclk.com/portal/wts/ue%5EcmQ6fDTqbb7gFaA2TyqmveE4b6dzMN9fA7fPsTa
LOL. A cut-n-paste hit piece that tries to spin FUD 👺 out of the PFS endpoint. Everyone knows that the endpoint was changed to OS (the gold standard) well before the data were unblinded.
Give your FUD 👺 a rest already!
The FUDster 👺 made it up. The company had not stated when the LOI was submitted.
Be careful of anonymous posters pretending to be experts.
Congrats on your IBRX investment... +29% today
If Investor and frrol are buying then it's likely a good indication we're near the bottom. After all, they've seen the "script."
I get your point. He obviously felt like venting, as this has been a long wait under perpetual collusive manipulation.
Not a bad thing to diversify one's spec plays. Though, he'll be kicking himself if approval, or partnership, comes sooner than later.
Paid bashers are rather easy to spot... they post untruths multiple times daily. Do you know anyone like that?
It's a free world. He gave his reason... to make an investment elsewhere and needed the funds.
I did the same with another biotech I was large in. Decided to sell half of it and invest in nwbo. I just didn't publicize it.
He's still an nwbo shareholder. I don't see a problem. He hasn't been a mindless basher. On the contrary... a sensible and valuable contributor.
Interesting...
Certainly, we don't know what is meant by "franchise", but it could be as simple as licensing out the technology to others who can produce it for their designated markets, including use in combo therapies.
The corrupt HFs/MMs are naked-shorting and wash-trading the hell out of the stock to create an illusion of failure. All for the benefit of their WS associates to buy in cheaply. We're just waiting for this charade to exhaust itself before buying back in.
The corrupt HFs/MMs are naked-shorting the hell out of the stock to create an illusion of failure. All for the benefit of their WS associates to buy in cheaply. Me... adding with every dip in SP.
That's certainly the kind of simpleton response/attack expected from a lowly paid FUDster 👺
...defending the tribe.
What you're not divulging (perhaps hiding) is that Fraudstein is a hired gun (mouthpiece)... hired by the same collusive HF network that hires the host of FUDsters who occupy this board and other social media platforms. Correct, AF doesn't "control" the SP directly; however, he (and his associate FUDsters) work to control the narrative... the fake & twisted narrative, providing a smokescreen for the evil doers (HFs) to do their dirty SP manipulation work. The smokescreen you/they create gives corrupt HFs something to "point to" if ever questioned. This is all well known and witnessed by those who've been in the market for many years. The challenge for honest investors/traders is to anticipate their manipulation and trade it.
Criminals and racketeers (i.e. KG and his hired FUDsters) always punch back with attacks to protect the criminally collusive tribe.
Let's see how much of the collusive short positions start covering today. Looks like a big buying/reloading opportunity with this collusive HF manipulative take down.
A franchise arrangement, or even the announcement of an intent, would escalate the SP sufficiently. I doubt any BP suitor would want to have to mess with and undo such relationships... and, therefore, might prompt a serious offer from the get-go.
"Franchise" was mentioned in their PR. Whether that means a commercial franchise or a term for their vaccine platform is the basis for speculation, but a commercial franchise could certainly be implemented... and would make perfect sense.
You're the loyal shareholder who continues to hold while bashing away. We're very familiar with how the FUDsters 👺 and their handlers operate before there's approval. This is no surprise... thus, we trade it. Hope you're adding at these manipulated lows! Good luck!
And yet you're still a shareholder. LOL. Tell us, genius, are you accumulating?
That is totally bogus and an oversimplification to say the least. To assume each arm exhibited the same level of placebo affect is naïve... and certainly shows how biotech isn't for everyone.
All aspects of the trial introduces elements that can adversely affect the placebo result, especially in the case where hopeful parents are answering test questions on behalf of the patient. The fact that no other Rett trial has ever produced such an extraordinarily large placebo effect suggests there are unusual conditions to it. One was mentioned by Walter E Kaufmann, MD, Chief Scientific Officer of Anavex commented, “We believe that a high placebo response may have masked the therapeutic effect of this innovative orally available molecule. High placebo responses are well documented especially in pediatric clinical studies. Although data analysis is ongoing, the early conclusion is that the placebo rate could have been higher in the study due to a slight imbalance in disease severity at baseline, across the treatment arms, and the 2 to 1 drug to placebo randomization ratio." The other is the lack of SAEs, which results in a truly blinded trial. Unlike trofinetide, where due to the side effects and lack thereof in the placebo group, parents virtually "knew" whether their daughters were on the drug or not. Thus, the trofinetide trail had more realistic placebo results than that of blarcamesine... where hopeful parents were "seeing" improvements that weren't really there. Those perceived improvements were likely the result of positive feedback from the patient to the positive influence of the parents. Had there been gastro issues with blarcamesine, it would be a good bet that the "placebo effect" would've been much lower, in the absence of an SAE (i.e. less hopeful parents). In fact, it wouldn't have taken much of a reduced placebo result for the RSBQ to be stat. sig. at the arbitrary p-value of .05 (compared to the calculated .063). Another factor, that negatively impacted the results, was that most of the interviews were done remotely, rather in person (due to Covid).
For the trofinetide trial, where parents virtually knew that their daughters were on the drug (due to gastro issues), they still couldn't bias their evaluation to a higher "hopeful" average result beyond -5.1 (which is less than the blarcamesine placebo result) because the true benefit was only marginal.
We'll see what the regulators have to say in review of the total trial data, OLE, RWE and perhaps the influence of the Rett Syndrome org. Deciding to run another trial, as a conservative measure, doesn't mean that all regulators have reviewed the data.
It's possible that the scope of the review could include PDD and perhaps Rett, in addition to AD... since the target for each is S1R.
...working for their HF handlers.
AACR in love with mRNA cancer vaccines, even with their yet-to-be-proven and likely limited efficacy. Boy, are they going to be surprised when DCVax-L gets approved.
https://www.fiercebiotech.com/biotech/aacr-24-cancer-vaccines-get-reintroduction-technology-finally-comes-together?utm_medium=email&utm_source=nl&utm_campaign=LS-NL-FierceBiotech&oly_enc_id=2560A2054734H1W
And yet you're still an investor. One who continues to hold shares as he continues to bash the CEO and drug, all the while his handlers take the price down with collusive coordination. That's real loyalty, I tell you!
And yet you're still a loyal shareholder. 👺
Unlike NWBO, they have no pivotal results yet... nothing has been submitted, but the FDA is waiting on the BPs to submit. SMH
This is why it's advantageous for NWBO to pursue UK first.
'We're open for business': FDA's Peter Marks says agency ready to review novel cancer vaccines despite unknowns
We can always count on "associates" to come to the defense. Must protect the tribe, right?
Yeah, it certainly helps to be privy to the collusive HF handlers' "script", doesn't it? No doubt, it's much easier to make a profit knowing that another planned short attack was in the works with the CTAD AD readout and to sell ahead of it... as opposed to having to rely on one's own anticipations of their actions, which is certainly not as accurate or guaranteed. Makes it that much easier to be playing with the house's (i.e. retail's) money, as one claims.
These postings by Anavex may very well be indicative and suggestive to the scope of the content in the forthcoming peer-reviewed journal article. AD. PDD, and perhaps more?
This sort of suggests, as I've been speculating, that the PDD data will likely be included with the AD data in a comprehensive peer-reviewed article on the efficacy and safety of blarcamesine. It would make complete sense. We'll soon see...
Here it is; just for you... 🖕
I sell every manipulated SP pop that your handlers orchestrate... because they always walk it back down, where one can reload. Again, tell your handlers 'thanks' for me. $$$
Damn right... reloaded all 100k shares by EOD. Tell your handlers 'thanks' for me! $$$
Yep, the collusive manipulators have to cover their collusive short positions eventually...
I'll gladly take a $10k profit on a quick 100k-sh sale and a reload .10 lower... while holding a large core position.
Bought back half (50k) and will buy the rest back EOD. So, go pound sand, FUDster!
More accurately... the capitulation post 20% gain is nearing exhaustion and about to charge higher, through the .65 resistance. I'll be reloading yesterday's sold shares soon ~.58.